February 2003

Jane S. Ricciuti, RPh, MS

Disclosures

February 19, 2003

Antilipemic Agents

Lopid

(gemfibrozil) Tablets

Manufacturer: Pfizer, Inc.

Drug Approval Classification: Supplemental NDA (approval date: 1/15/03)

Adverse Effects: Lopid (gemfibrozil) labeling was revised to include the following statement:

Cases of cholelithiasis have been reported with gemfibrozil therapy.

Lopid (gemfibrozil) Tablets Letter

Lopid (gemfibrozil) Tablets

1 2 3 4 5 6 7 8 9 10 11

Next Section

Cite this: February 2003 - Medscape - Feb 20, 2003.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

February 2003

Antilipemic Agents

Tables

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback